This page is for one very specific problem: a name sounds settled because it is loud online, but its real status is different in the UK and the U.S. Use it to separate current UK reality from U.S. approval, trial momentum, and brand-led confusion.
The answer changes depending on whether you mean brand, molecule, route, indication or country.
Use the country, route and indication together before deciding what a medicine name means for UK access.
| Name | Current UK meaning | Current U.S. meaning | Main risk of misunderstanding |
|---|---|---|---|
| Rybelsus | Current oral semaglutide tablet anchor in diabetes context. | Also a real oral semaglutide medicine, but not the whole oral market story. | Overextending it into a broad UK weight-management tablet claim. |
| Wegovy pill | Not a settled current UK access answer. | Part of the U.S. oral semaglutide conversation and branding landscape. | Treating U.S. brand and label momentum as if it already settled UK route status. |
| Ozempic pill | Usually a search phrase or route confusion point. | May reflect current U.S. oral semaglutide visibility, depending on what source is being quoted. | Letting a familiar brand name replace a proper product explanation. |
| Foundayo | Important future-facing name, not a current UK access answer. | U.S.-approved oral GLP-1 development linked to orforglipron. | Mistaking U.S. approval for UK launch or prescribing availability. |
| Orlistat | Current oral weight-management option, but not GLP-1. | Separate non-GLP-1 route. | Confusing any oral option with an oral GLP-1 treatment. |